Clinical Trial Update: Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine [Phase 3]

View source ↗

Summary

Phase 3 study evaluates the immunogenicity and safety of a Group A, C, Y and W135 meningococcal polysaccharide vaccine for meningitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis

Drugs mentioned

• Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine (Meningococcal polysaccharide vaccine (groups A, C, Y, W-135))

Snippet

Sponsor: Beijing Minhai Biotechnology Co., Ltd | Conditions: Meningitis | Phase 3 | Status: COMPLETED